OncLive | Bringing the Global Oncology Community Together

Melflufen and dexamethasone demonstrated encouraging activity in patients with relapsed/refractory multiple myeloma with and without extramedullary disease, with response rates higher than those observed in prior studies... Read More >>

IMW 2019: Daratumumab Plus VRd Shows Improved sCR in Transplant-Eligible, Newly Diagnosed Myeloma

IMW 2019: Iberdomide Shows Promise in Heavily Pretreated Multiple Myeloma

SOHO 2019: Novel Combos Are Shaking Up the CLL Landscape

IMW 2019: Isatuximab Triplet Showcases Encouraging PFS in High-Risk Multiple Myeloma

SOHO 2019: Myelofibrosis Management Makes Strides With JAK Inhibitors, But Work Remains

View More Stories >>

View Conference Coverage

17th International Myeloma Workshop

2019 Society of Hematologic Oncology Annual Meeting

2019 World Conference on Lung Cancer

Charlotte Plasma Cell Disorder Congress

State of the Science Summit on Breast Cancer in Long Island

Dr. Castillo on the Use of Venetoclax in Waldenstrom Macroglobulinemia

Dr. Usmani on Impact of BCMA on the Myeloma Treatment Landscape

Dr. William on Brentuximab Vedotin/Lenalidomide in T-Cell Lymphoma

OncLive houses thousands of videos that provide updates and information.
See more Videos

Role of PARP Inhibitors in Prostate Cancer

Considerations for Genetic Testing in Prostate Cancer

Sequencing in Nonmetastatic and Metastatic CRPC

Patient Selection for Radium-223 in mCRPC

Reducing Risk of Fracture in Metastatic CRPC

AR-V7 as a Predictive Biomarker in Metastatic CRPC

Frontline Therapy in Newly Diagnosed Metastatic HSPC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Acute GVHD: An Evolving Treatment Paradigm

Treating Acute GVHD With Novel Strategies

Novel Therapies for BRAF+ Colorectal Cancer

Targeting BRAF and MEK in Colorectal Cancer

The Future of Personalized Therapy in Advanced HCC

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured

New Directions in Chronic Lymphocytic Leukemia Care: A Review of 2019 Treatment Guideline Updates

Pivotal trial data were presented at the 2018 ASH Annual Meeting that demonstrated promising results for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (SLL).

View more >>>

Featured

TRK Inhibitors: Precision Medicine in Oncology

Benjamin Levy, MD; Mark Agulnik, MD; Marcia Brose, MD, PhD; Edward Kim, MD; John Marshall, MD; and Philip Agop Philip, MD, PhD, FRCP, discuss the use of TRK inhibitors in oncology.

View more >>>

Featured Video

Dr. Esteva on the Future of Biosimilars in Breast Cancer

Francisco J. Esteva, MD, PhD, director, breast medical oncology program, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, discusses the future use of biosimilars in breast cancer within the United States. View now

FDA Guidelines in Male Breast Cancer, Encouraging Data in Breast Cancer and Myeloma, and More